ArticleRevista do Instituto de Medicina Tropical de Sao Paulo2025
Clinical, epidemiological, and laboratory analysis of hospitalized and fatal COVID-19 cases in the first fully vaccinated municipality in Northeast Brazil.
Article in Revista do Instituto de Medicina Tropical de Sao Paulo, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Guaramiranga, Ceara State, Brazil, a tourist city 105.5 km from the capital Fortaleza, was a pilot site for vaccinating 100% of its 4,002 adult population with the first dose against COVID-19. The city received 3,328 CoronaVac, 1,685 AstraZeneca, and 174 Pfizer-BioNTech doses (5,187 in total). Vaccination with the first dose occurred from January 20, 2021 to April 1, 2022. This study analyzed hospitalized patients' epidemiological, clinical, and laboratory characteristics and deaths from COVID-19 in Guaramiranga from March 2020 to December 2022. In total, nine cases required hospitalization, seven of which resulted in death. Patients' median age at death equaled 87 (64-95) years. Only one was male, and five had incomplete vaccination schedules before their hospitalization. Hypertension and diabetes configured the most frequent comorbidities, whereas common symptoms at admission included fever (four cases), cough (four cases), and dyspnea (five cases). Of these nine patients, 4 received anticoagulants and corticosteroids; 6, oxygen supplementation; 2, oseltamivir; and 3, empirical antibiotic for pneumonia. The mean interval between the last vaccine dose and hospitalization totaled 128 days (28-326; SD 137). These findings highlight incomplete vaccination, a prolonged interval since last doses, comorbidities, and advanced age as key factors associated with severe cases and deaths and emphasize the protective role of high vaccination coverage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.